全文获取类型
收费全文 | 4497篇 |
免费 | 192篇 |
国内免费 | 27篇 |
专业分类
耳鼻咽喉 | 26篇 |
儿科学 | 119篇 |
妇产科学 | 42篇 |
基础医学 | 528篇 |
口腔科学 | 110篇 |
临床医学 | 333篇 |
内科学 | 1284篇 |
皮肤病学 | 65篇 |
神经病学 | 332篇 |
特种医学 | 180篇 |
外科学 | 718篇 |
综合类 | 35篇 |
一般理论 | 1篇 |
预防医学 | 163篇 |
眼科学 | 26篇 |
药学 | 281篇 |
中国医学 | 8篇 |
肿瘤学 | 465篇 |
出版年
2023年 | 26篇 |
2022年 | 50篇 |
2021年 | 98篇 |
2020年 | 42篇 |
2019年 | 76篇 |
2018年 | 85篇 |
2017年 | 54篇 |
2016年 | 72篇 |
2015年 | 73篇 |
2014年 | 91篇 |
2013年 | 131篇 |
2012年 | 206篇 |
2011年 | 258篇 |
2010年 | 147篇 |
2009年 | 140篇 |
2008年 | 258篇 |
2007年 | 241篇 |
2006年 | 230篇 |
2005年 | 226篇 |
2004年 | 204篇 |
2003年 | 201篇 |
2002年 | 218篇 |
2001年 | 113篇 |
2000年 | 124篇 |
1999年 | 115篇 |
1998年 | 72篇 |
1997年 | 33篇 |
1996年 | 35篇 |
1995年 | 31篇 |
1994年 | 24篇 |
1993年 | 29篇 |
1992年 | 87篇 |
1991年 | 83篇 |
1990年 | 86篇 |
1989年 | 76篇 |
1988年 | 67篇 |
1987年 | 68篇 |
1986年 | 71篇 |
1985年 | 63篇 |
1984年 | 47篇 |
1983年 | 34篇 |
1979年 | 46篇 |
1977年 | 27篇 |
1976年 | 16篇 |
1975年 | 24篇 |
1974年 | 27篇 |
1973年 | 20篇 |
1972年 | 23篇 |
1971年 | 21篇 |
1969年 | 18篇 |
排序方式: 共有4716条查询结果,搜索用时 15 毫秒
1.
Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Hideyuki Nomura Akira Kawano Kazuhiro Takahashi Kazufumi Dohmen Takeaki Satoh Koichi Azuma Makoto Nakamuta Toshimasa Koyanagi Kazuhiro Kotoh Shinji Shimoda Jun Hayashi The Kyushu University Liver Disease Study Group 《Journal of gastroenterology and hepatology》2015,30(8):1309-1316
2.
3.
In Vivo Molecular Imaging Characterizes Pulmonary Gene Expression During Experimental Lung Transplantation 总被引:2,自引:0,他引:2
Sekhar Dharmarajan Makio Hayama James Kozlowski Takaaki Ishiyama Mikio Okazaki Phillip Factor G. Alexander Patterson Daniel P. Schuster 《American journal of transplantation》2005,5(6):1216-1225
Experimental gene therapy is a promising strategy to prevent ischemia-reperfusion (I/R) injury and allograft rejection after lung transplantation, and methods will eventually be needed to characterize pulmonary transgene expression in vivo in humans. Therefore, we studied positron emission tomography (PET) as a means of performing in vivo molecular imaging in rodent models of lung transplantation. Rats were transfected endotracheally with adenovirus encoding a fusion gene of a mutant Herpes simplex virus-1 thymidine kinase and the green fluorescent protein gene (the former serving as an imaging reporter gene). Twenty-four hours after transfection, lungs were transplanted in groups representing normal transplantation, I/R injury and acute allograft rejection. Imaging was obtained either 24 h after transplantation to study reperfusion injury or 4 days after transplantation to study graft rejection. After imaging, lungs were excised and analyzed for thymidine kinase activity. Imaging detected transgene expression in transplanted lungs even in the presence of acute rejection or I/R injury. The PET imaging signal correlated with in vitro lung tissue assays of thymidine kinase activity (r(2) = 0.534). Thus, noninvasive molecular imaging with PET is a feasible, sensitive and quantitative method for characterizing pulmonary transgene expression in experimental lung transplantation. 相似文献
4.
5.
6.
Kiichiro Hashimoto Naohide Mori Takao Tamesa Toshimasa Okada Shigeto Kawauchi Atsunori Oga Tomoko Furuya Akira Tangoku Masaaki Oka Kohsuke Sasaki 《Modern pathology》2004,17(6):617-622
To clarify the genetic aberrations involved in the development and progression of hepatitis C virus-associated hepatocellular carcinoma (HCV-HCC), we investigated DNA copy number aberrations (DCNAs) in 19 surgically resected HCCs by conventional CGH and array CGH. Conventional CGH revealed that increases of DNA copy number were frequent at 1q (79% of the cases), 8q (37%), 6p (32%), and 10p (32%) and that decreases were frequent at 17p (79%), 16q (58%), 4q (53%), 13q (42%), 10q (37%), 1p (32%), and 8p (32%). In general, genes that showed DCNAs by array CGH were usually located in chromosomal regions with DCNAs detected by conventional CGH analysis. Increases in copy numbers of the LAMC2, TGFB2, and AKT3 genes (located on 1q) and decreases in copy numbers of FGR/SRC2 and CYLD (located on 1p and 16q, respectively) were observed in more than 30% of tumors, including small, well-differentiated carcinomas. These findings suggest that these genes are associated with the development of HCV-HCC. Increases of MOS, MYC, EXT1, and PTK2 (located on 8q) were detected exclusively in moderately and poorly differentiated tumors, suggesting that these alterations contribute to tumor progression. In conclusion, chromosomal and array CGH technologies allow identification of genes involved in the development and progression of HCV-HCC. 相似文献
7.
Satoru Miyawaki Ryuichi Yamazaki Takehiko Harada Shigehiko Takanashi Tadashi Nagashima Hiroshi Nakaguchi Ryo Okazaki Kazuhito Yamazaki Yasuo Ishida Akira Matsuno 《Journal of clinical neuroscience》2007,14(5):481-484
Skull metastasis of thyroid carcinoma is rare. The majority of skull metastases of thyroid carcinoma are of the follicular subtype, rather than thyroid papillary carcinoma. In this report, a 55-year-old woman with skull metastasis from thyroid papillary carcinoma is presented. The metastatic lesion of the skull was hypervascular and osteolytic, and the bleeding was profuse during resection. There have been only four reports of skull metastasis from thyroid papillary carcinoma. The mean period from the initial diagnosis of thyroid carcinoma until the detection of skull metastasis is 23.3 years, whereas in this patient, it was about 2 years. Therefore, in the clinical course of thyroid papillary carcinoma, skull metastasis should be considered, and the patient should be meticulously followed up. 相似文献
8.
9.
10.
M Ishii O Abe H Okura N Okazaki T Kawai Y Saito N Sawabu Y Takamizawa T Takeuchi H Niitani 《Gan to kagaku ryoho. Cancer & chemotherapy》1987,14(8):2548-2555
The CA-50 enzyme immunoassay kit (EIA kit) that has been developed with the use of C-50 monoclonal antibody prepared by L. Lindholm et al. was evaluated for diagnosis of human cancer. The levels of CA-50 in the sera were determined using this kit supplied from Mitsui Pharmaceuticals, Inc. Co. in 759 healthy donors, 728 patients with benign disease and 1,263 untreated patients with cancer. A CA-50 concentration of 40 U/ml of serum was used as the cut-off value. Patients with pancreatic cancer and patients with bile duct cancer had high positive incidence of 75% and 68%, respectively, compared with a low positive incidence of under 40% in patients with other cancers. On the other hand, positive rates in patients with benign disease were as low as 13%. Comparison of the serum levels of CA-50 with CA19-9 in the same samples did not exhibit complete positive correlation in patients with pancreatic cancer, patients with bile duct cancer and patients with liver cancer. These findings indicated that C-50 antibody reacted with two epitopes of CA19-9 and sialosyllactotetraose. From the above results, the usefulness of CA-50 as a tumor marker for pancreatic cancer and bile duct cancer was recognized with this EIA kit. 相似文献